Article Title: Management of early stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty
Authors: Roy, A.C., Shapiro, J., Burge, M., Karapetis, CS., Pavlakis, N., Segelov, E., Chau, I., Lordick, F., Chen, LT., Barbour, A., Tebbutt, N1., & Price, T.
Journal: Expert Review of Anticancer Therapy
DOI: http://dx.doi.org/10.1080/14737140.2020.1746185
The figure source and the footnote for the algorithm 1 and 2 were missed when the article was first published.
These have now been included in the corrected version.
Algorithm 1: Oesophageal cancer
Footnote:
* Carboplatin Paclitaxel RT (if T1-3, N0-1 CROSS regimen), Cisplatin-5FU RT (if bulky disease > T3, N2-3)
~ Cisplatin 5FU RT or FOLFOX RT (select cases- carboplatin paclitaxel RT), RT dose: 50.4Gy
# FLOT
## After thorough restaging to rule out metastatic disease
$ To be performed in high-volume centres: optional if inadequate response to CRT or local relapse.
Adapted from: Oesophageal Cancer: ESMO Clinical Practice Guidelines; Ann Oncol (2016) 27 (suppl 5): v50-v57 [38]
Algorithm 2: OGJ and Gastric Adenocarcinoma
Footnote:
Chemotherapy regimes:
* FLOT
# Carboplatin Paclitaxel RT (if T1-3, N0-1- CROSS regimen) or Cisplatin-5FU RT (if bulky disease or >T3 or N2)
~ Capecitabine Oxaliplatin
## After thorough restaging to rule out metastatic disease
^ 5FU- RT (McDonalds Protocol) (if T3 N+, and/or < D2 resection, R1 resection). RT dose: 45Gy. For +ve margins boost 5.4Gy
Adapted from: Adapted from Gastric Cancer: ESMO Clinical Practice Guidelines; Ann Oncol (2016) 27 (suppl 5): v38-v49 [54]